{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:12:48Z","timestamp":1743149568851,"version":"3.40.3"},"publisher-location":"Cham","reference-count":47,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319160177"},{"type":"electronic","value":"9783319160184"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-16018-4_5","type":"book-chapter","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T07:30:30Z","timestamp":1428737430000},"page":"95-111","source":"Crossref","is-referenced-by-count":2,"title":["Chronic Kidney Disease"],"prefix":"10.1007","author":[{"given":"Alice","family":"Santos-Silva","sequence":"first","affiliation":[]},{"given":"El\u00edsio","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Alves","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ki.2011.198","volume":"80","author":"RG Fassett","year":"2011","unstructured":"Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806\u201321.","journal-title":"Kidney Int"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1741-7015-4-30","volume":"4","author":"O Lenz","year":"2006","unstructured":"Lenz O, Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey. BMC Med. 2006;4:30\u20139.","journal-title":"BMC Med"},{"issue":"suppl","key":"5_CR3","first-page":"63","volume":"3","author":"KDIGO 2012","year":"2013","unstructured":"KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int. 2013;3(suppl):63\u201372.","journal-title":"Kidney Int"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ndt\/gft479","volume":"29","author":"A Levin","year":"2014","unstructured":"Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O, CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014;29:1037\u201347.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR5","first-page":"119","volume":"30","author":"M Junyent","year":"2010","unstructured":"Junyent M, Martinez M, Borras M, et al. Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrologia. 2010;30:119\u201326.","journal-title":"Nefrologia"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1046\/j.1523-1755.63.s84.45.x","volume":"84","author":"DC Wheeler","year":"2003","unstructured":"Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int Suppl. 2003;84:S201\u20133.","journal-title":"Kidney Int Suppl"},{"key":"5_CR8","first-page":"29","volume":"57","author":"M Dajak","year":"2011","unstructured":"Dajak M, Ignjatovi\u0107 S, Stojimirovi\u0107 B, Gaji\u0107 S, Majki\u0107-Singh N. Evaluation of renal damage by urinary beta-trace protein in patients with chronic kidney disease. Clin Lab. 2011;57:29\u201336.","journal-title":"Clin Lab"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/ATVBAHA.114.303465","volume":"34","author":"K Matsushita","year":"2014","unstructured":"Matsushita K, Sang Y, Ballew SH, Astor BC, Hoogeveen RC, Solomon SD, Ballantyne CM, Woodward M, Coresh J. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014;34:1770\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR11","doi-asserted-by":"crossref","unstructured":"Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fischer MJ, He J, Kallem RR, Kusek JW, Master SR, Miller ER 3rd, Rosas SE, Steigerwalt S, Tao K, Weir MR, Hsu CY; CRIC Study Investigators. Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015; 65(2):267\u201374.","DOI":"10.1053\/j.ajkd.2014.07.025"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/j.ajkd.2012.05.014","volume":"60","author":"CA Peralta","year":"2012","unstructured":"Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2012;60:904\u201311.","journal-title":"Am J Kidney Dis"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/01.tp.0000295982.78039.ef","volume":"84","author":"MM van Timmeren","year":"2007","unstructured":"van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2007;84:1625\u201330.","journal-title":"Transplantation"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/geno.1997.4896","volume":"45","author":"JB Cowland","year":"1997","unstructured":"Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45:17\u201323.","journal-title":"Genomics"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jacc.2010.11.051","volume":"57","author":"M Haase","year":"2011","unstructured":"Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin (NGAL)-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cca.2013.05.020","volume":"424","author":"A Kamijo-Ikemori","year":"2013","unstructured":"Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K, Kimura K. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013;424:104\u20138.","journal-title":"Clin Chim Acta"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11010-005-9047-9","volume":"284","author":"A Kamijo","year":"2006","unstructured":"Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175\u201382.","journal-title":"Mol Cell Biochem"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.transproceed.2013.11.130","volume":"46","author":"J Yang","year":"2014","unstructured":"Yang J, Choi HM, Seo MY, Lee JY, Kim K, Jun H, Jung CW, Park KT, Kim MG, Jo SK, Cho W, Kim HK. Urine liver-type fatty acid-binding protein predicts graft outcome up to 2 years after kidney transplantation. Transplant Proc. 2014;46:376\u201380.","journal-title":"Transplant Proc"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/ndt\/17.6.1005","volume":"17","author":"JH H\u00f6rstrup","year":"2002","unstructured":"H\u00f6rstrup JH, Gehrmann M, Schneider B, Pl\u00f6ger A, Froese P, Schirop T, Kampf D, Frei U, Neumann R, Eckardt KU. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant. 2002;17:1005\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10157-013-0814-8","volume":"18","author":"K Hanamura","year":"2014","unstructured":"Hanamura K, Tojo A, Fujita T. Urinary and glomerular podocytes in patients with chronic kidney diseases. Clin Exp Nephrol. 2014;18:95\u2013103.","journal-title":"Clin Exp Nephrol"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","volume":"358","author":"C Zoccali","year":"2001","unstructured":"Zoccali C, Bode-B\u00f6ger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Fermo I, Fr\u00f6lich JC, B\u00f6ger RH. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113\u20137.","journal-title":"Lancet"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1440-1797.2012.01659.x","volume":"18","author":"V Raptis","year":"2013","unstructured":"Raptis V, Kapoulas S, Grekas D. Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology. 2013;18:11\u201321.","journal-title":"Nephrology"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157340310791162659","volume":"6","author":"L Sibal","year":"2010","unstructured":"Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82\u201390.","journal-title":"Curr Cardiol Rev"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000355776","volume":"39","author":"J Eiselta","year":"2014","unstructured":"Eiselta J, Rajdlb D, Racekb J, Vostr\u00fdb M, Rulcov\u00e1a K, Wirtha J. Asymmetric dimethylarginine and progression of chronic kidney disease \u2013 a one-year follow-up study. Kidney Blood Press Res. 2014;39:50\u20137.","journal-title":"Kidney Blood Press Res"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ndt\/gfg533","volume":"19","author":"AA Eddy","year":"2004","unstructured":"Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant. 2004;19:277\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10875-007-9168-x","volume":"28","author":"E Costa","year":"2008","unstructured":"Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Faria MS, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28:268\u201375.","journal-title":"J Clin Immunol"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1097\/01.ASN.0000146422.45434.35","volume":"15","author":"L Fried","year":"2004","unstructured":"Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184\u201391.","journal-title":"J Am Soc Nephrol"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2369-9-9","volume":"9","author":"C Keller","year":"2008","unstructured":"Keller C, Katz R, Cushman M, et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008;9:9.","journal-title":"BMC Nephrol"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","volume":"68","author":"M Tonelli","year":"2005","unstructured":"Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68:237\u201345.","journal-title":"Kidney Int"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.ki.5000021","volume":"69","author":"J Lin","year":"2006","unstructured":"Lin J, Hu FB, Rimm EB, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 2006;69:336\u201342.","journal-title":"Kidney Int"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1111\/j.1523-1755.2005.00338.x","volume":"67","author":"F Mallamaci","year":"2005","unstructured":"Mallamaci F, Tripepi G, Cutrupi S, et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 2005;67:2330\u20137.","journal-title":"Kidney Int"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1523-1755.2005.00551.x","volume":"68","author":"V Menon","year":"2005","unstructured":"Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766\u201372.","journal-title":"Kidney Int"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/ndt\/gfq471","volume":"26","author":"A Upadhyay","year":"2011","unstructured":"Upadhyay A, Larson MG, Guo C-Y, Vasan RS, Lipinska I, O\u2019Donnell CJ, Kathiresan S, Meigs JB, Keaney Jr JF, Rong J, Benjamin EJ, Fox CS. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011;26:920\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"c167","DOI":"10.1159\/000320116","volume":"117","author":"T Kawaguchi","year":"2011","unstructured":"Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, Kurokawa K, Canaud B, Lameire N, Port FK, Pisoni RL. C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract. 2011;117:c167\u201378.","journal-title":"Nephron Clin Pract"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1525-139X.2010.00784.x","volume":"23","author":"JJ Carrero","year":"2010","unstructured":"Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease \u2013 what have we learned in 10 years? Semin Dial. 2010;23:498\u2013509.","journal-title":"Semin Dial"},{"issue":"5","key":"5_CR37","doi-asserted-by":"publisher","first-page":"e63493","DOI":"10.1371\/journal.pone.0063493","volume":"8","author":"A Witasp","year":"2013","unstructured":"Witasp A, Ryd\u00e9n M, Carrero JJ, Qureshi AR, Nordfors L, N\u00e4slund E, Hammarqvist F, Arefin S, Kublickiene K, Stenvinkel P. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8(5):e63493.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"5_CR38","doi-asserted-by":"publisher","first-page":"i54","DOI":"10.1093\/ndt\/gft342","volume":"29","author":"AB Sanz","year":"2014","unstructured":"Sanz AB, Izquierdo MC, Sanchez-Ni\u00f1o MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant. 2014;29 Suppl 1:i54\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/MNH.0b013e32834ad504","volume":"20","author":"T Miyamoto","year":"2011","unstructured":"Miyamoto T, Carrero JJ, Stenvinkelb P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1681\/ASN.2010070760","volume":"22","author":"AM Hung","year":"2011","unstructured":"Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol. 2011;22:437\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-09-2581","volume":"16","author":"T Puchalski","year":"2010","unstructured":"Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010;16:1652\u201361.","journal-title":"Clin Cancer Res"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","volume":"103","author":"JF Rossi","year":"2010","unstructured":"Rossi JF, N\u00e9grier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154\u201362.","journal-title":"Br J Cancer"},{"key":"5_CR43","unstructured":"Jones SA, Fraser DJ, Fielding CA, Jones GW. Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant. 2014. http:\/\/ndt.oxfordjournals.org\/content\/early\/2014\/07\/09\/ndt.gfu233.full.pdf+html."},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1681\/ASN.2013050545","volume":"25","author":"J Himmelfarb","year":"2014","unstructured":"Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, Kaplan M, Chonchol M, Hakim RM. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol. 2014;25:623\u201333.","journal-title":"J Am Soc Nephrol"},{"key":"5_CR45","first-page":"461","volume":"7","author":"A Ahmadi","year":"2013","unstructured":"Ahmadi A, Mazooji N, Roozbeh J, Mazloom Z, Hasanzade J. Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients. Iran J Kidney Dis. 2013;7:461\u20137.","journal-title":"Iran J Kidney Dis"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1093\/ndt\/gfq715","volume":"26","author":"D Kirmizis","year":"2011","unstructured":"Kirmizis D, Papagianni A, Belechri AM, Memmos D. Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant. 2011;26:2296\u2013301.","journal-title":"Nephrol Dial Transplant"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1440-1797.2012.01597.x","volume":"17","author":"J Deng","year":"2012","unstructured":"Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis. Nephrology. 2012;17:545\u201351.","journal-title":"Nephrology"}],"container-title":["Biomarkers of Cardiometabolic Risk, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-16018-4_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T15:03:58Z","timestamp":1675263838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-16018-4_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319160177","9783319160184"],"references-count":47,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-16018-4_5","relation":{},"subject":[],"published":{"date-parts":[[2015]]}}}